This led to the development of inhibitors to NF-κB pathway as a potential strategy for cancer therapy. Further, NF-κB is activated constitutively in human pancreatic cancer cell lines but not in normal pancreatic tissues suggesting that NF-κB plays a crucial role in pancreatic cancer progression. Here, NFKB1 is linked to cancer.